Kite Analysis: $17M Raised
What is Kite?
Kite develops innovative video solutions for businesses, enhancing communication and collaboration through advanced video technology and tools.
Founded
2022
Product Features & Capabilities
- Chimeric Antigen Receptor (CAR) T-cell therapy, engineered autologous T cells, treatment for Diffuse Large B-cell Lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and Mantle Cell Lymphoma (MCL).
How much Kite raised
Series A - Raised:** $17 million
Announced:** January 28, 2019Lead Investor: - Trinity Ventures
Competitors Overview
Kite Pharma's main competitors in the CAR T cell therapy market include:
- Luminary Therapeutics: This company is focused on overcoming challenges in the CAR T industry and has developed a novel BAFF CAR T-cell therapy aimed at treating systemic lupus erythematosus. Their approach emphasizes i
Investors
- Arie Belldegrun
- Bellco Capital
- InterWest Partners
- Alta Partners
- BB Biotech
Market Focus
Kite Pharma primarily focuses on the biotechnology industry, specifically in the development of cancer immunotherapy products, with an emphasis on genetically engineered autologous CAR T cell therapy to treat cancer.
See something that needs updating? Suggest edits to this profile.